IntoCell Inc
PublicIntoCell Inc is now publicly traded
The data on this page reflects IntoCell Inc's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
May 23, 2025
Last Round
Growth Equity
Aug 2, 2024
Est. Valuation at Exit
$167.09M
Total Funding Raised
$22.79M
Company Overview
IntoCell Inc operates in Biotech and is based in Daejeon, Daejeon. Its recorded funding history includes a Growth Equity round in August 2024.
IntoCell Inc is a biotechnology company that develops an antibody-drug conjugate (ADC) platform for the research and development of biopharmaceuticals.
Sector
Biotech
AI Layer
Non-AI
IntoCell Inc Comparables
Compare IntoCell Inc with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trioar | 84% | |
| Pinotbio | 84% | |
| Novelty Nobility Inc. | 83% |
For institutional investors. Book with your work email.
IntoCell Inc Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | May 23, 2025 | ||||
| Growth Equity | Aug 2, 2024 | ||||
| Seed | Apr 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
IntoCell Inc Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mirae Asset Securities | IPO |
IntoCell Inc Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.